KEYNOTE-590 and CHECKMATE-648 phase III trials demonstrated good survival benefits of anti-PD-1 in combination with chemotherapy for the first-line treatment of advanced unresectable/metastatic ESCC. Here, PDCD1 is linked to esophageal squamous cell carcinoma.